Memantine agonist action at dopamine D2High receptors
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Memantine is reported to improve symptoms in moderate cases of Alzheimer's disease and Parkinson's disease, but is also known to trigger psychosis in some Parkinson patients. Because these clinical features suggested a possible dopamine component of memantine action, we measured the potency of memantine on the functional high‐affinity state of dopamine D2 receptors, or D2 High. Using [3 H]domperidone to label D2 receptors, the memantine dissociation constant at D2 High was 917 ± 23 nM for rat striatal D2 receptors and 137 ± 19 nM for human cloned D2Long receptors. The memantine dissociation constant for striatal N‐methyl‐D‐aspartate (NMDA) receptors labeled by [3 H]MK 801 was 2200 ± 400 nM. Memantine stimulated the incorporation of [35 S]GTP‐γ‐S into D2‐expressing Chinese Hamster Ovary cells with a dissociation constant of 1200 ± 400 nM. Memantine, between 200 and 2000 nM, directly acted on D2 High to inhibit the release of prolactin from isolated anterior pituitary cells in culture. Because the memantine potencies at NMDA receptors and dopamine D2 High receptors are of a similar order of magnitude, it is likely that the clinical features of memantine can be attributed to its action at both types of receptors. Synapse 62:149–153, 2008. © 2007 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics
Seeman, P., Ko, F., & Tallerico, T. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001682 · Cited by 200 · cited 2×
“It is possible, for example, that the properties of memantine may be similar to those of phencyclidine and ketamine which have similar potencies for the NMDA receptor and the high-affinity state of the dopamine D2 receptor (Kapur and Seeman, 2001; Seeman and Lasaga, 2005; Seeman et al., 2005).”
Self-citation
Cited by
The Lipophilic Bullet Hits the Targets: Medicinal Chemistry of Adamantane Derivatives
Wanka, L., Iqbal, K., & Schreiner, P. R. (2013) · Chemical Reviews · doi:10.1021/cr100264t · Cited by 696
Role of central dopamine in pain and analgesia
Wood, P. B. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.5.781 · Cited by 370
Dopamine, Immunity, and Disease
Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J., & Gaskill, P. J. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000618 · Cited by 308
Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine
Zemek, F., Drtinova, L., Nepovimova, E., Sepsova, V., Korabecny, J., Klimes, J., & Kuca, K. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.914168 · Cited by 299
Sani, G., Serra, G., Kotzalidis, G. D., Romano, S., Tamorri, S. M., Manfredi, G., Caloro, M., Telesforo, C. L., Caltagirone, S. S., Panaccione, I., et al. (2012) · CNS Drugs · doi:10.2165/11634390-000000000-00000 · Cited by 273
Metadata
- Authors
- Seeman, P., Caruso, C., & Lasaga, M.
- Venue
- Synapse
- Publisher
- Wiley
- Published
- 2007-11-13
- Volume
- 62
- Issue
- 2
- Pages
- 149-153
- ISSN
- 0887-4476 (ISSN-L)
- 1098-2396
- OpenAlex
- W2090211805
- Cited by
- 120
- References
- 2
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.